Inhibrx (INBX) news
Recent news
Inhibrx Biosciences, Inc.: H.C. Wainwright initiates coverage with buy rating and target price $245
H.C. Wainwright & Co. has initiated coverage of Inhibrx Biosciences, Inc. (NYSE: INHB) with a "Buy" rating and a target price of $245 per share. The decision follows a review of the company’s recent developments and its pipeline of therapeutic candidates. Inhibrx, a clinical-stage biotechnology…
AInvest Wire · 7d agoInhibrx Q2 operating expenses USD 32.149 million
Inhibrx Biosciences, Inc. (Nasdaq: INBX) reported operating expenses of $32.149 million for the second quarter of 2025, representing a significant decline compared to the $160.998 million recorded in the same period of 2024. The reduction in expenses is primarily attributed to completion of the 101…
AInvest Wire · Aug 13, 2026Inhibrx Q2 operating income USD -32.149 million
Inhibrx Biosciences, Inc. (Nasdaq: INBX) reported an operating loss of $32.149 million for the second quarter of 2024, according to its most recent financial results. This figure reflects the company’s ongoing operational performance following its separation from the former parent entity, Inhibrx,…
AInvest Wire · Aug 13, 2026Inhibrx Q2 EPS USD -2.34
Inhibrx Biosciences, Inc. (NASDAQ: INBX) reported net loss of $2.34 per share for the second quarter of 2026, according to its latest earnings report. This figure reflects the company's ongoing investment in clinical development and research activities. The company has two programs in ongoing…
AInvest Wire · Aug 13, 2026Inhibrx expanding facility to $500.0M
AInvest Wire · Jul 16, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.